Introduction Capmatinib, a highly potent and selective MET receptor inhibitor, has demonstrated significant antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC) who have MET exon 14 skipping mutations or MET amplification (1). This synopsis highlights key findings from the GEOMETRY mono-1 study, a pivotal phase 2 trial, u
Pancytopenia, a rare presentation of hyperthyroidism
830 Reached2 Comments
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1007 Reached2 Comments
Treatment of Recurrent Adult Medulloblastoma
2601 Reached1 Comments4 Likes
Total Hip Arthroplasty in a Patient with Congenital Insensitivity to Pain
358 Reached4 Comments5 Likes
Chronic Cough in Adolescent
282 Reached1 Comments6 Likes